Retatrutide vs Semaglutide
| Attribute | Retatrutide Triple agonist (GLP-1/GIP/Glucagon) | Semaglutide GLP-1 receptor agonist |
|---|---|---|
| Category | Weight Loss & Metabolism | Weight Loss & Metabolism |
| Best known for | Triple-receptor metabolic research | Weight loss and blood sugar research |
| In plain English | Retatrutide pulls three levers — appetite, insulin response, and energy expenditure via glucagon. Trials have shown the largest weight reductions of any incretin to date. | Semaglutide mimics the hormone your gut releases when you eat. The brain reads it as 'we're full,' appetite drops, and stomach emptying slows down. |
| How it works | GLP-1 reduces appetite. GIP enhances insulin response. Glucagon receptor activation increases energy expenditure and fat oxidation. | Activates the GLP-1 receptor in the pancreas, brain, and gut — increasing insulin secretion, slowing gastric emptying, and reducing appetite through hypothalamic signaling. |
| Researchers study | Obesity, hepatic steatosis, and metabolic syndrome. | Glycemic control, weight reduction, cardiovascular outcomes, and emerging research in addiction and neuroinflammation. |
| Internet discussion | Treated as the 'next big thing' in metabolic forums. Discussion centers on side effect profile vs tirzepatide. | The internet talks about semaglutide constantly — 'Ozempic face,' food noise reduction, alcohol cravings dropping, and dose-titration questions. |
Retatrutide
Triple-receptor metabolic research
Retatrutide pulls three levers — appetite, insulin response, and energy expenditure via glucagon. Trials have shown the largest weight reductions of any incretin to date.
GLP-1 reduces appetite. GIP enhances insulin response. Glucagon receptor activation increases energy expenditure and fat oxidation.
Obesity, hepatic steatosis, and metabolic syndrome.
Treated as the 'next big thing' in metabolic forums. Discussion centers on side effect profile vs tirzepatide.
Retatrutide is an investigational triple agonist showing the largest weight-loss signals in metabolic research to date.
Semaglutide
Weight loss and blood sugar research
Semaglutide mimics the hormone your gut releases when you eat. The brain reads it as 'we're full,' appetite drops, and stomach emptying slows down.
Activates the GLP-1 receptor in the pancreas, brain, and gut — increasing insulin secretion, slowing gastric emptying, and reducing appetite through hypothalamic signaling.
Glycemic control, weight reduction, cardiovascular outcomes, and emerging research in addiction and neuroinflammation.
The internet talks about semaglutide constantly — 'Ozempic face,' food noise reduction, alcohol cravings dropping, and dose-titration questions.
Semaglutide is the reference GLP-1 agonist — well-studied for blood sugar control and significant weight reduction.